Avanza Medical Research Center | Gulf Coast Office Center
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:
Participant must be able to swallow a tablet
For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
Participants must weigh at least 15 kilograms (kg)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,633 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
There will be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal